AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02269371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
Study NCT02269371 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
Study NCT03841955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC with high pressure tolerance
Description: Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
Study NCT03841955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rontine central venous catheter
Description: Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
Study NCT04532658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching program
Description: * Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement
Study NCT03264885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Incentive Care
Description: ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
Study NCT03389139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared spectroscopy (spinal anesthesia)
Description: effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
Study NCT03389139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared spectroscopy (general anesthesia)
Description: effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
Study NCT01487876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV DNA vaccine
Description: HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
Study NCT01487876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
Study NCT03663764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin a1
Description: All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
Study NCT03663764 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
Study NCT03663764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
Study NCT03021577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital Atherectomy System (OAS)
Description: The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
Study NCT03021577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablator Rotational Atherectomy System
Description: The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
Study NCT03021577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
Study NCT04034394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromoxibustion
Description: Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
Study NCT01893281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Testosterone Solution
Description: Administered topically to axillae.
Study NCT04034394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education
Description: Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
Study NCT04387981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-orvepitant
Description: Oral solution of \[14C\]-orvepitant
Study NCT01310309 — intervention group
Intervention type: DEVICE
Intervention: Coronary artery placement of a drug-eluting stent
Description: Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
Study NCT04570527 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study NCT00200174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene followed by combination therapy
Description: Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
Study NCT03089398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Coronary Revascularization (isolated LIMA-LAD)
Description: sternal-sparing, off-pump, isolated LIMA-LAD revascularization
Study NCT03089398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Coronary Revascularization (PCI)
Description: percutaneous revascularization of at least one non-LAD target
Study NCT03089398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
Study NCT02177955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 7.5 mg Midazolam
Description: 7.5 mg midazolam 45 minutes before surgery
Study NCT00200174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane followed by combination therapy
Description: Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
Study NCT03421145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Oral Rinse
Description: The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
Study NCT03421145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control Oral Rinse
Description: The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
Study NCT03421145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerioShield™ Oral Health Rinse
Description: PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
Study NCT03421145 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Purified bottled water containing no active ingredients.
Study NCT00637000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine soluble film
Description: Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
Study NCT00637000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone film strip
Description: Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
Study NCT00637000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
Study NCT03611777 — intervention group
Intervention type: DRUG
Intervention: Inhaled corticosteroid
Description: Drug
Study NCT04471480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC/PD-1 inhibitor/anlotinib
Description: chemotherapy and immunotherapy plus antiangiogenic therapy
Study NCT04471480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TC/PD-1 inhibitor/anlotinib
Description: chemotherapy and immunotherapy plus antiangiogenic therapy
Study NCT00703599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Stem cells
Description: Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
Study NCT02177955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg diazepam
Description: 10 mg midazolam 45 minutes before surgery
Study NCT00007878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00007878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00007878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00007878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00007878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06541366 — intervention group
Intervention type: OTHER
Intervention: case-control study
Description: physical examination and Survey Form
Study NCT01758302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple physical task
Description: Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
Study NCT01758302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complex physical task
Description: Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
Study NCT02074046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study NCT04216199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care Ultrasound
Description: Point of care Ultrasound
Study NCT02987374 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2011-2012 Fluzone IIV3 (IM)
Description: 2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
Study NCT04431908 — intervention group
Intervention type: DEVICE
Intervention: olfactory device
Description: A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
Study NCT00006471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
Study NCT02748135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 20mg/kg
Description: bi-weekly intravenous doses of TB-403 20mg/kg
Study NCT02748135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 50mg/kg
Description: bi-weekly intravenous doses of TB-403 50mg/kg
Study NCT02748135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 100mg/kg
Description: bi-weekly intravenous doses of TB-403 100mg/kg
Study NCT02748135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-403 175mg/kg
Description: bi-weekly intravenous doses of TB-403 175mg/kg
Study NCT02749994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT02749994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02749994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study NCT02074046 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study NCT00586599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measurement of inflammatory markers
Description: measuring inflammatory markers and comparing to controls.
Study NCT01758302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cookies
Description: Participants are asked to taste test chocolate chip cookies
Study NCT01758302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetables
Description: Participants are asked to taste test raw celery or radishes
Study NCT01758302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No physical task
Description: As a control, for 2 of the arms, participants are not asked to engage in a physical task
Study NCT04775602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: 18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
Study NCT02955472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 150mg
Description: A new formulation(3rd.) of Pregabalin CR tablet
Study NCT02955472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 150mg
Description: A new formulation(1st.) of Pregabalin CR tablet
Study NCT02008591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique
Description: Three different techniques, using the same medications (bupivacaine and fentanyl)
Study NCT02343003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
Study NCT02343003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Delivery of corticosteroid into knee by injection with needle to reduce knee pain
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYD
Description: Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
Study NCT02222350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg DS-8500a tablet
Study NCT02222350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg DS-8500a tablet
Study NCT02222350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00653770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP85A
Description: Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for HYD
Description: Placebo to match HYD tablets administered orally every 24 hours.
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for HYD
Description: Placebo to match HYD tablets administered orally every 24 hours.
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
Study NCT02243241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
Study NCT03137654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Affective Training
Description: Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
Study NCT03137654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Training
Description: Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
Study NCT00886067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral, single dose
Study NCT00886067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2-[18F]-F-A85380
Description: iv, single dose
Study NCT00653770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)
Study NCT01939886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine - Artesunate
Study NCT01939886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study NCT02450630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strenghtened referral of children
Description: Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
Study NCT02475135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC
Description: A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
Study NCT00952796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: moxifloxacin 400mg once daily (IV form, 60minutes)
Study NCT00952796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin/sulbactam
Description: ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
Study NCT05849883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg Capsules
Description: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
Study NCT05849883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg Capsules
Description: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
Study NCT00355147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician stroke guideline adherence
Description: Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors